Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oriola Oyj (ORIOLA.HE)
Espoo, FI
Oriola Oyj, headquartered in Espoo, Finland, and established in 1907, is a leading player in the wholesale distribution of pharmaceuticals and a wide array of health and wellness products across Sweden, Finland, and international markets. Their extensive product portfolio includes vitamins, nutritional supplements, sports-specific items, wound care solutions, beauty and cosmetic goods, vaccines, and over-the-counter medications. Beyond distribution, Oriola provides a comprehensive suite of expert services. These encompass pharmaceutical logistics, specialized import of licensed medicines, personalized dose dispensing, and support for research pharmacies. The company also offers commercial data insights, clinical trial management, regulatory affairs, quality assurance, medical and scientific advisory, market access strategies, real-world evidence generation, sales support, medical translation, pharmacovigilance, medical information, and patient assistance programs, alongside general advisory services. Oriola serves a diverse client base, ranging from pharmaceutical manufacturers and pharmacies to veterinarians, hospitals, healthcare providers, specialty stores, retailers, and e-commerce businesses.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.78% | -3.92% | -7.83% | -25.17% | -23.88% | -24.53% | -18.24% | -37.82% | -52.27% | -79.08% | -45.49% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+13.5% ★ Q1'26: -88.9% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%-36.4% Q1'26: +64.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+2.6% ★ Q1'26: -47.0% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%+0.1% Q1'26: +3.8% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%+5.2% Q1'26: +22.1% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+1.6% Q1'26: +2.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×4.10× ★ Q1'26: 3.45× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.68B
est: 1.68B (-0.1%)
|
1.91B
est: 1.89B (+1.0%)
|
662.84M
657.36M – 667.52M
-64.9% YoY
|
692.74M
684.57M – 702.34M
+4.5% YoY
|
722.75M
715.48M – 730.36M
+4.3% YoY
|
2.31B
2.28B – 2.33B
+219.0% YoY
|
| EBITDA |
-700.0K
est: 25.59M (-102.7%)
|
19.10M
est: 28.72M (-33.5%)
|
10.09M
10.00M – 10.16M
-64.9% YoY
|
10.54M
10.42M – 10.69M
+4.5% YoY
|
11.00M
10.89M – 11.11M
+4.3% YoY
|
35.08M
34.73M – 35.45M
+219.0% YoY
|
| EBIT |
-14.30M
est: 7.72M (-285.1%)
|
1.40M
est: 8.67M (-83.9%)
|
3.04M
3.02M – 3.07M
-64.9% YoY
|
3.18M
3.14M – 3.23M
+4.5% YoY
|
3.32M
3.29M – 3.36M
+4.3% YoY
|
10.59M
10.48M – 10.70M
+219.0% YoY
|
| Net Income |
-20.10M
|
-27.20M
est: -4.52M (-502.1%)
|
10.33M
7.38M – 13.28M
+328.6% YoY
|
16.65M
15.02M – 24.41M
+61.2% YoY
|
20.53M
16.62M – 31.17M
+23.3% YoY
|
19.78M
19.52M – 20.05M
-3.6% YoY
|
| SGA |
30.90M
est: 14.52M (+112.9%)
|
—
est: 16.29M (-100.0%)
|
5.72M
5.68M – 5.76M
-64.9% YoY
|
5.98M
5.91M – 6.06M
+4.5% YoY
|
6.24M
6.18M – 6.31M
+4.3% YoY
|
19.90M
19.70M – 20.11M
+219.0% YoY
|
| EPS |
-0.11
|
-0.15
est: -0.02 (-511.9%)
|
0.06
0.04 – 0.07
+339.6% YoY
|
0.11
0.08 – 0.13
+85.2% YoY
|
0.12
0.09 – 0.17
+11.5% YoY
|
0.11
0.11 – 0.11
-11.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Katarina Gabrielson | President & Chief Executive Officer | 560.5K | female |
| Katja Lundell | Executive Vice President of Advisory Services | — | female |
| Maria Lundell | Chief People Officer | — | female |
| Mats Danielsson | Chief Financial Officer | — | male |
| Mikael Nurmi | Chief Digital Officer | — | male |
| Mikael Wegmüller | Vice President of Communications & Sustainability | — | male |
| Petter Sandstrom | General Counsel & Secretary to the Board | — | male |
| Satu Nylén | Executive Vice President of Services & Products | — | female |
| Stig Tornell | Executive VP of Sales | — | male |
| Tua Stenius-Örnhjelm | Manager of Investor Relations & Sustainability | — | female |
| Tuomas Tiilikainen | Chief Supply Chain Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ORIOLA.HE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
